Margaret Dugan insider trades: BeOne Medicines (ONC) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Margaret reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | ONC | ↓ Sell | 212 | $309.60 | $66K | Direct | May 27, 2026 (5d) |
| Oct 16, 2025 | SDGR | ↓ Sell | 1,395 | $21.07 | $29K | Direct | Oct 17, 2025 (1d) |
| Oct 15, 2024 | SDGR | ↓ Sell | 1,531 | $17.78 | $27K | Direct | Oct 16, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ONC insiders
Open-market trades in the last 12 months
About Margaret Dugan's insider trades
Margaret Dugan is a director at BeOne Medicines (ONC). Since Oct 15, 2024, Margaret has reported no open-market purchases and 3 sales worth $122K on SEC Form 4. In the last 12 months: 1 sale ($66K).
Their filings also include grants and awards (13 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.